reports
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation w...
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has entered into a settlement agreement with Unichem Laboratories Ltd. (Unichem) resolving patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New J...
Axsome Therapeutics Joins the American Migraine Foundation to Highligh...
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is joining the migraine advocacy community to raise awareness of unmet patient needs during Migraine & Headache Awareness Month this June. “Education plays a crucial role in addressing the stigma associated with migrai...
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is supporting Alzheimer’s & Brain Awareness Month this June, to help increase awareness and understanding of the challenges Alzheimer’s disease (AD) presents to patients, their caregivers, and their loved ones, and the importance of brain and mental health as cornerstones of overall health. ...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Axsome will participate in two upcoming investor conferences. The conference details are as follows: William Blair 44th Annual Growth Stock Conference, on Wednesday, June 5, at 2 p.m. Central Time. Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will present a corporate overview...
Axsome Therapeutics Inc: 2 directors
Two Directors at Axsome Therapeutics Inc sold/sold after exercising options 18,407 shares at between 74.313USD and 75.175USD. The significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Impr...
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024 Data on solriamfetol featured in two oral plenary sessions NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced five presentations, including two featured oral plenary presentations, on solriamfetol at SLEEP 2024, the 38th annual meeting of the...
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 A...
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that data from its industry-leading portfolio of novel products for CNS disorders will be presented at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held May 28-31, 2024, in Miami Bea...
New Angi Report Finds Nearly 90% of Skilled Tradespeople Satisfied in ...
New Angi Report Finds Nearly 90% of Skilled Tradespeople Satisfied in Their Careers DENVER, May 21, 2024 (GLOBE NEWSWIRE) -- , a leading and comprehensive solution for improving and maintaining homes, today released its Skilled Trades in America Report. The report highlights a trend that stands in stark contrast to anxieties in many sectors: exceptionally high job satisfaction in the skilled trades industry. While concerns about AI replacing jobs are prevalent across industries, skilled trades professionals report feeling secure. According to Angi’s data, a staggering 90% of tradespeople...
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics to Present at Upcoming Investor Conferences NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabuteau will participate in ...
Angi Inc. Earnings Release Available on Company’s Website
Angi Inc. Earnings Release Available on Company’s Website DENVER, May 07, 2024 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) posted its first quarter financial results on the investor relations section of its website at . As announced previously, Angi Inc. and IAC will host a conference call to discuss both companies’ respective first quarter results and to answer questions. The call will be held on Wednesday, May 8, 2024, at 8:30 a.m. ET. Joey Levin, CEO of IAC and Chairman of Angi Inc., Jeffrey Kip, CEO of Angi Inc. and Christopher Halpin, Executive Vice President, CFO and COO of IAC, wi...
This National Signing Day, Angi Aims to Boost Hiring in the Trades
This National Signing Day, Angi Aims to Boost Hiring in the Trades Angi expands partnership with trades job platform BlueRecruit and launches new scholarship program to raise awareness of the benefits of the trades and help close the labor gap DENVER, May 06, 2024 (GLOBE NEWSWIRE) -- , a leading and comprehensive solution for improving and maintaining homes, today launched several new initiatives in advance of May 7th’s National Signing Day–a day to acknowledge and celebrate students who pursue an undergraduate or graduate trade school training program. Launched today, the Angi Trade Up...
Axsome Therapeutics Reports First Quarter 2024 Financial Results and P...
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-year growth Contract executed with second large group purchasing organization (GPO) for potential coverage of Auvelity Positive pivotal Phase 3 trial results of AXS-12 in narcolepsy announced Topline results of ADVANCE-2 Phase 3 tr...
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
Axsome Therapeutics Recognizes May as Mental Health Awareness Month NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Mental Health America, during May’s Mental Health Month to raise awareness of the importance of mental health as a key element of overall health. Axsome is committed to the millions of individuals living with mental health conditions...
- Carole Braudeau
- Carole Braudeau
- Carole Braudeau
Angi Inc. to Announce Q1 2024 Earnings on May 7th and Host Earnings Co...
Angi Inc. to Announce Q1 2024 Earnings on May 7th and Host Earnings Conference Call on May 8th DENVER, April 16, 2024 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, May 7, 2024, Angi Inc. (NASDAQ: ANGI) will post its first quarter results at . On Wednesday May 8, 2024, at 8:30 a.m. ET, Angi Inc. and IAC will host a conference call to answer questions regarding the companies’ respective first quarter results. The live audiocast and replay will be open to the public through the investor relations section of the Angi site at . About Angi Inc. Angi (NASDAQ: ANGI) helps...
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at th...
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced present...
Axsome Therapeutics to Report First Quarter 2024 Financial Results on ...
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2024 on Monday, May 6, 2024, before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 a.m. Eastern Time on May 6, 2024, to discuss these results and provide a business ...
Angi Appoints Jeff Kip as CEO
Angi Appoints Jeff Kip as CEO DENVER, April 08, 2024 (GLOBE NEWSWIRE) -- Angi (NASDAQ: ANGI), the leading and most comprehensive solution for all home care needs, today announced the appointment of Angi President and long-time IAC and Angi executive Jeff Kip to CEO, succeeding Joey Levin. As CEO, Mr. Kip will lead Angi’s executive team, overseeing strategy and daily management of the company. Mr. Levin, CEO of IAC, will continue as Chairman of the Angi Board of Directors. All changes are effective immediately. “Through multiple roles, Jeff Kip has been a student of the Angi business, fir...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.